RxDoctor Payments Data

Anna Do, MD

Ophthalmology · San Diego, CANPI 1588058721

Payments from drug & device makers

$22,662in general payments, 2019–2025

Across 163 payments — averaging $139.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$19K
  • Alcon$746
  • NEW World Medical,inc.$503
  • Bausch & Lomb Americas Inc.$445
  • Glaukos Corporation$347
  • Johnson & Johnson Surgical Vision, Inc.$300
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$1,3756%
  • Speaking & faculty fees$12,82557%
  • Travel & lodging$2,1469%
  • Food & beverage$6,27628%
  • Education$400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,662 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$159,065
Medicare patients
383
Services billed
1,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine82$106,970
Cyclosporine80$59,418
XiidraLifitegrast35$41,046
VyzultaLatanoprostene Bunod56$36,415
LumiganBimatoprost47$30,736
RocklatanNetarsudil Mesylat/Latanoprost29$16,358
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol48$12,565
Prednisolone Acetate201$8,976
Timolol Maleate307$8,938
Latanoprost667$8,590
Alphagan PBrimonidine Tartrate12$7,356
Travoprost58$7,330
RhopressaNetarsudil Mesylate19$7,150
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat325$6,117
Brimonidine Tartrate94$5,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$18,572$145,062141 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$445$77,46191 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$281$23,50848 claims
AlconSimbrinza$746$4,70912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →